Back to search results

Inhaled Cannabis for PTSD in Veterans

This study is looking at whether inhaled high THC Cannabis can help reduce symptoms of Post Traumatic Stress Disorder (PTSD) in U.S. veterans. Researchers will compare high THC Cannabis (dried cannabis flower with 18-22% THC) to a placebo cannabis (dried cannabis flower with less than 1% THC). To join, you must be at least 18 years old, a veteran with PTSD for at least 6 months, and have moderate to severe PTSD symptoms. The study will measure changes in your PTSD symptom severity using a special assessment called the CAPS-5-R. The current status of this study is unclear, and it plans to enroll 320 participants.

Study design
This is an interventional study comparing high THC Cannabis to a placebo in 320 participants. It uses a parallel study design to re-examine the use of inhaled cannabis for PTSD symptoms.
What's involved
You would be assessed for PTSD symptoms at the beginning of the study (Day 1) and at the end of treatment (Day 35).
Compensation
Not stated in the trial record.
Follow-up
Your PTSD symptoms will be measured at the end of treatment (Day 35).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07224698

Inhaled Cannabis for Treatment of PTSD

Not Yet Recruiting
PHASE2Ages 18+InterventionalTreatment
Multidisciplinary Association for Psychedelic Studies
~320 participants
Updated 2026-08-11 on ClinicalTrials.gov
What's tested:High THC CannabisPlacebo cannabis

At a glance

Recruiting sites

Site status isn't published for this study.

What they're measuring
Efficacy: Compare changes in PTSD symptom severity in the high THC vs placebo cannabis group as measured by Clinician Administered PTSD Scale for DSM-5, Revised (CAPS-5-R).
Measured over Intro 1 (Day 1), End of Treatment (Day 35)

Conditions

Post Traumatic Stress Disorder PTSD

Explore related trials

Post-Traumatic Stress Disorder

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Participants with a history of atrial fibrillation, atrial tachycardia, atrial flutter or paroxysmal supraventricular tachycardia or any other arrhythmia associated with a bypass tract may be enrolled only if they have been successfully treated with ablation and have not had recurrent arrhythmia for at least one year off all antiarrhythmic drugs, or are under adequate and stable pharmacologic treatment for atrial fibrillation for at least a year, as confirmed by a cardiologist. 10. Have a current or history of chronic obstructive pulmonary disease or asthma. 11. Have a current diagnosis or evidence of significant or uncontrolled hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, gastrointestinal, renal, hepatic, immunocompromising, or neurological disease according to CI's discretion. 12. Have any current problem or presence of clinical feature which, in the opinion of the CI or Medical Monitor, might interfere with or prevent appropriate study participation. 13. Have any known allergies to cannabis or contraindication for inhalation of cannabis. 14. Are not able to give adequate informed consent. 15. Insufficient ability to report on symptoms to make a valid assessment on any required instrument. 16. Are not able to attend required face-to-face visits or those who plan to move out of the area within the treatment period.

What this trial measures

  • Efficacy: Compare changes in PTSD symptom severity in the high THC vs placebo cannabis group as measured by Clinician Administered PTSD Scale for DSM-5, Revised (CAPS-5-R).Intro 1 (Day 1), End of Treatment (Day 35)

    The CAPS-5 is a 30-item semi-structured interview assessing PTSD in the past month through diagnostic and symptom severity scores anchored to a DSM-5 defined traumatic event. The CAPS-5 produces a Total Severity Score based on severity of PTSD domains described in the DSM-5, as well as a categorical rating indicating whether a participant meets PTSD diagnostic criteria. CAPS-5 Total Symptom Severity scores range from 0 to 80 with higher values indicating greater symptom severity. CAPS-5 assigns PTSD diagnosis as being present or absent.